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Abstract
We propose a novel adaptive design for clinical trials with time-to-event outcomes and co-
variates (which may consist of or include biomarkers). Our method is based on the expected
entropy of the posterior distribution of a proportional hazards model. The expected entropy is
evaluated as a function of a patient’s covariates, and the information gained due to a patient
is defined as the decrease in the corresponding entropy. Candidate patients are only recruited
onto the trial if they are likely to provide sufficient information. Patients with covariates that
are deemed uninformative are filtered out. A special case is where all patients are recruited,
and we determine the optimal treatment arm allocation. This adaptive design has the ad-
vantage of potentially elucidating the relationship between covariates, treatments, and survival
probabilities using fewer patients, albeit at the cost of rejecting some candidates. We assess the
performance of our adaptive design using data from the German Breast Cancer Study group
and numerical simulations of a biomarker validation trial.
1 Introduction
Adaptive clinical trials offer a potentially more efficient and ethical way to conduct clinical trials.
Covariate-adaptive designs try to ensure that the distributions of covariates across different arms
are balanced, thus resulting in more comparable cohorts on each arm (Pocock and Simon, 1975;
Taves, 1974). Response-adaptive randomisation attempts to allocate more patients to the effective
treatment arms. As the trial progresses and more information is acquired on the efficacies of each
treatment arm the allocation probabilities shift towards the more effective treatments. Zhang and
Rosenberger (2007) develop an optimal response-adaptive design under exponential and Weibull
parametric models for time-to-event outcomes. See Yin (2012) for a good overview of adaptive
designs.
We regard the primary goal of a clinical trial as establishing a statistical relationship between
covariates, treatments, and survival outcomes. As we will show, not all patients on a trial provide
the same amount of statistical information. Some covariate values are more informative than others.
In addition, the informativeness of a covariate value will depend on what has been observed so far
in the trial. As an example, consider two scenarios where a patient with particular covariate values
is available for recruitment. In the first scenario another patient with precisely the same covariate
values has already been recruited. In the second scenario suppose the candidate’s covariates come
from a region of covariate space that has not previously been sampled. Intuitively we expect the
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candidate to be more informative in the second scenario since they provide access to previously
unobserved covariates values and outcomes.
Our aim in this paper is to address a practical question: given limited resources and the obser-
vation that not all patients are equally informative, what is the optimal way to conduct a clinical
trial? We propose that it may be advantageous to selectively recruit and allocate patients on the
basis of how much information they are likely to provide. Covariates are measured for candidate
patients, and based on those values and what has been inferred from the trial up to that point
a recruitment probability is computed. In other words, we filter out patients that are unlikely to
significantly reduce the uncertainty surrounding model parameters.
Predictive biomarkers, which indicate whether a patient is likely to respond well to a particular
treatment or not, are increasingly useful in the drive towards personalised medicine and targeted
therapy. A potential application of our selective-recruitment design would be to validate a biomarker
by looking at treatment-biomarker interaction terms in a proportional hazards model. We test this
using numerical simulations. Sargent et al. (2005) discuss alternative adaptive designs for validating
predictive biomarkers.
Our filtering approach is similar in spirit to some existing designs. Freidlin and Simon (2005)
propose a trial design which attempts to find a gene signature that will identify a subset of ‘sensitive’
patients who are more likely to respond to the treatment. In a randomised discontinuation design
(Rosner et al., 2002) patients who fail to respond to a treatment in the first phase of the trial are
dropped from the second part, thereby isolating a responsive subset of patients with a stronger
statistical signal. Another type of trial known as ‘enrichment designs’ (Temple, 2010) enrich the
recruited cohort with patients who are more likely to have the event of interest. For example,
patients with a particular biomarker. Given that more events of interest are observed greater
statistical power can be achieved within the enriched cohort.
We assume a proportional hazards model with a constant baseline hazard rate. The entropy
of the posterior distribution is a useful way to quantify our uncertainty regarding the model pa-
rameters. As the trial progresses, and the space of plausible parameter values shrinks, the entropy
decreases. The informativeness of a candidate is defined as the reduction in expected entropy in the
hypothetical scenario where they are added to the cohort of existing recruits. The ideal candidate
at time t is defined as the patient that would achieve the greatest possible reduction in expected
entropy. By comparing the current candidate to the ideal candidate we can obtain a recruitment
probability. The posterior is constructed using outcomes from all patients accrued up until time t.
Patients who have not experienced any events are considered to be right-censored. Therefore, the
recruitment probability changes dynamically as more events and patients are observed. An arm
allocation probability can also be computed based on which arm has the lowest expected entropy.
We also implement this in a more traditional setting where all candidates are recruited.
In Section 2 we provide the mathematical details and describe some approximations which are
required. Results from experimental data generated by the German Breast Cancer Study group and
numerical simulations are presented in Sections 3 and 4 respectively. Discussion on the practical
applicability of our approach and concluding remarks are given in Section 5.
2
2 An information based adaptive protocol
2.1 Proportional hazards model
Suppose that Nt patients have been recruited onto the trial at time t. Observed data are denoted
by Dt = {(x1, t1,∆1), . . . , (xNt , tNt ,∆Nt)} where xi ∈ Rd is a vector of covariates for patient i (this
vector may include biomarker values or treatment indicator variables). If patient i is censored then
∆i = 0 and ti is the time of censoring, otherwise the primary event occurred at time ti and ∆i = 1.
Patients who have not experienced any event by t are considered right censored. We assume a
proportional hazards model with a constant baseline hazard rate λ ∈ (0,∞):
h(ti|xi, λ,β) = λeβ·xi for i = 1, . . . , Nt (1)
where β ∈ Rd is a vector of regression coefficients. The covariates are assumed to be drawn from a
known population distribution p(x). The data likelihood is
p(Dt|λ,β) =
Nt∏
i=1
(
λeβ·xi
)∆i
exp(−λtieβ·xi)p(xi). (2)
Using Bayes’ rule we can write the posterior as
p(λ,β|Dt,θ) = p(Dt|λ,β)p(λ|θ)p(β|θ)
p(Dt|θ) (3)
where p(Dt|θ) is the marginal likelihood. The vector θ contains hyperparameters that are required
for the prior distributions. For the prior over λ we choose λ ∼ Gamma(κ0, χ0), with shape and
scale hyperparameters κ0 and χ0 respectively, and β ∼ N (0, α20I). The value of θ = (κ0, χ0, α20) is
fixed and we will henceforth drop the dependence on θ for the sake of notational compactness.
2.2 Entropy as a measure of patient informativeness
At time t we have recruited Nt patients onto the trial. Suppose that a candidate patient with
covariates x∗ has presented and we wish to estimate how much information we expect the candidate
to provide if they are to be recruited. The information gain is defined as the reduction in the
expected entropy of the posterior (3). The entropy is defined as
h(Dt) = −〈log p(λ,β|Dt)〉p(λ,β|Dt) . (4)
The notation 〈· · · 〉p denotes the expectation with respect to the density p. We then add the
candidate to the existing cohort and take the expectation with respect to the unknown t∗:
H(x∗|Dt) = 〈h(Dt ∪ {x∗, t∗})〉p(t∗|x∗,Dt) (5)
where the argument of h is the union of Dt and the additional uncensored observation {x∗, t∗} and
where
p(t∗|x∗, Dt) = 〈p(t∗|x∗, λ,β)〉p(λ,β|Dt) . (6)
The time-to-event density is p(t∗|x∗, λ,β) = λeβ·x∗exp(−λt∗eβ·x∗). This can be used to define an
objective function E that will be used to determine the recruitment probability for the candidate
E(x∗|Dt) = h(Dt)−H(x∗|Dt). (7)
3
2.3 Mathematical approximations
The expectation (4) is analytically intractable. Consequently, we develop a variational approx-
imation of the the posterior q(λ,β) ≈ p(λ,β|Dt) with q(λ,β) = q(λ)q(β). The purpose of a
variational approximation is to approximate the posterior with a form that is more amenable to
analytical integration (Bishop, 2006, Chapter 10). For the variational distributions q we choose a
log-Normal distribution, log λ ∼ N (µ1, σ21), and a multivariate Normal distribution for the regres-
sion coefficients, β ∼ N (µ0,Σ0) with Σ0 = diag(σ201, . . . , σ20d). To achieve a ‘good’ approximation
we minimise the Kullback-Leibler divergence between the distributions q and p with respect to the
variational parameters (µ1, σ
2
1 ,µ0, σ
2
01, . . . , σ
2
0d):
KL(q||p) =
〈
log
[
q(λ)q(β)
p(λ,β|Dt)
]〉
q(λ)q(β)
= 〈log q(λ)〉q(λ) + 〈log q(β)〉q(β) − 〈log p(λ,β|Dt)〉q(λ)q(β) . (8)
This is convenient since the first two terms give the entropy of the variational distribution which is
required in (5). Equation (8) is explicitly calculated in Appendix A.
In addition, the expectations (5, 6) are analytically intractable. We make two further approxi-
mations:
1. p(t∗|x∗, λ,β) = δ(t∗ − tˆ) where tˆ = 〈t∗〉p(t∗|x∗,λ,β) = (λeβ·x
∗
)−1.
2. p(λ,β|Dt) = δ(λˆ− λ)δ(βˆ − β) where (λˆ, βˆ) = argmax(λ,β)p(λ,β|Dt).
The Dirac delta function δ(x) is loosely defined by δ(0) =∞ and is zero elsewhere. These approx-
imations allow evaluation of the integrals (5, 6) and, additionally, it is computationally faster to
obtain (λˆ, βˆ) rather than numerically integrating (5, 6). Combining the above approximations we
can write tˆ = (λˆeβˆ·x
∗
)−1 and obtain
Hˆ(x∗|Dt) = hˆ(Dt ∪ {x∗, tˆ}) (9)
hˆ(Dt) = −〈log q(λ)〉q(λ) − 〈log q(β)〉q(β) . (10)
These can be substituted into (7) to obtain an approximated objective function Eˆ(x∗|Dt). Evalua-
tion of these expressions require numerical optimisation of (3) and (8) in order to evaluate, but this
is computationally feasible. Note that estimates of λ and β could be unstable at the early stages of
the trial when few patients have been recruited. In this case, one could implement a ‘burn in’ phase
where selective recruitment only begins after a certain number of patients have been recruited.
2.4 Obtaining a recruitment and allocation probability
Once a candidate patient presents with covariates x∗ we would like to define a recruitment probabil-
ity ρ(x∗|Dt). In general, we can write x∗ = [y∗, z] where y∗ are clinical covariates or biomarkers and
z indicates the allocated treatment arm. Suppose there are K arms in total and z ∈ {z1, . . . , zK}
where zk indicates allocation to arm k. The first step is to define the allocation probability to
treatment arm k as
p(k|x∗, Dt) = Eˆ(y
∗, zk|Dt)∑K
j=1 Eˆ(y
∗, zj |Dt)
for k = 1, . . . ,K. (11)
4
Random
Adaptive
| ||
|
|
|||||
|| |
| || |||| ||| | |||||||||||||||||| ||||||||||| |||||||| ||||||||||
|
|||||||||||||||||||||||||||||||||||||
|||||||||
−2
0
2
4
0 2 4 6 8
Time t
Po
ste
rio
r E
nt
ro
py
(years)
Figure 1: Plot of the posterior entropy (10) for the RCT and ACT as a function of time.
The vertical ticks indicate times at which a patient was recruited. The sharp drop at ≈ 0.75
years corresponds to the first primary event occurring.
A treatment arm is chosen at random according to this distribution and is denoted by z∗. Secondly,
we define the ideal candidate as yI = argmaxyEˆ(y, z
∗|Dt). The ideal candidate would give us the
greatest reduction in expected entropy. A recruitment probability is given by
ρ(x∗|Dt) = f0
(
Eˆ(y∗, z∗|Dt)
Eˆ(yI , z
∗|Dt)
)
(12)
where f0 is some function that remains to be specified. Since the argument of f0 must lie in the
interval [0, 1] we can choose f0 to be the identity function in which case the closer the candidate is
to the ideal patient the higher the probability of recruitment. Alternatively, we can choose f0(s) =
θ(s − p0) for a specified threshold p0. The step function θ(s) = 0 if s ≤ 0 and θ(s) = 1 otherwise.
This results in deterministic recruitment. A more general option is f0(s) = (1 + tanh(s/β0− p0))/2
which is equivalent to deterministic recruitment when β0 → 0. This allows the practitioner to
implement a desired level of stringency in the recruitment process.
3 The German Breast Cancer Dataset
We applied our method to data obtained from the German Breast Cancer Study (GBCS) described
in Hosmer et al. (2008, Section 1.3). Our goal is to infer the parameters for a single covariate in
order to assess how our adaptive protocol performs. The data consist of time-to-event outcomes for
686 patients recruited between July 1984 and December 1989. There are eight covariates in total.
We decided to use tumour size (mm) for a univariate analysis because a good spread (1st quartile
= 20 mm, median = 25 mm, 3rd quartile = 35 mm) would make it suitable for filtering patients
according to the covariate. Importantly, the dataset also contains the date at which each patient
is diagnosed with primary node positive breast cancer so we can easily calculate the waiting-time
between patients. This allows us to effectively ‘re-run’ the trial. The primary event was recurrence.
To assess the information-adaptive design we decided to recruit a total of NT = 100 patients.
We used deterministic recruitment with a cutoff of p0 = 0.5. The trial was terminated after 10
years. We compared this to a randomised clinical trial (RCT) in which the first 100 patients are
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Ntotal Nreject tR λ β entropy
Full 686 0 67 0.13 0.36 (0.19,0.52), p = 6.1× 10−6 -4.54
ACT 100 278 31 0.11 0.44 (0.21,0.66), p = 4.2× 10−5 -3.49
RCT 100 0 11 0.14 0.11 (-0.27,0.48), p = 0.29 -2.83
Table 1: Inferred parameters and entropies of the full GBCS dataset (Full), the adaptive
clinical trial (ACT), and the randomised clinical trial (RCT). In brackets are 95 percent
confidence intervals and p is corresponding the p-value. Ntotal is the total number of recruits,
Nreject is the number of rejected candidates, and tR is the recruitment time in months.
recruited. The same proportional hazards model as Section 2.1 was used to analyse the RCT. The
covariate values were median-centred and rescaled by 25 mm. The population density was assumed
constant. We impose a uniform prior between ±1 for the ideal covariate xI . Hyperparameters were
set to (κ0, χ0, α
2
0) = (3, 1, 4).
It took approximately 1 year to recruit 100 patients onto the RCT. The adaptive clinical trial
(ACT) took approximately 2.5 years, during which a total of 278 patients were rejected. In Figure
1 the posterior entropies for both the ACT and RCT are plotted. Initially the entropies are largely
determined by the priors over λ and β but quickly drop as patients are recruited, although not
monotonically. In the first 2.5 years of the trial the RCT has a lower entropy which is presumably
due to the fact that more patients have been recruited compared to the ACT. Towards the end of
the trial the ACT has a lower entropy due to a more informative cohort. Both entropies continue
to decrease after recruitment has finished as more events are observed.
Table 1 shows the inferred model parameters (evaluated after 10 years) from the original dataset,
the ACT, and the RCT. The ACT results in a significant non-zero value for β that is close to the
value obtained using the full dataset (with N = 686). The RCT fails to infer any significant value.
In order to gain some intuition for how the recruitment probabilities are determined we have
plotted the expected entropy as a function of the covariate x at various time points in Figure 2. We
note that the function tends to have one maximum and two minima at x = ±1. This general shape
is due to the nature of the proportional hazards model since extreme values of x will diminish
the space of plausible parameter values more so than values close to zero, and consequently are
more informative. The dashed line is the entropy below which a candidate will be recruited. In
(a) the trial has started at t = 0 with two patients. There is a strong preference for individuals
towards ±1. The next candidate (at t = 34 days) had x∗ = −0.52 and so was recruited. In (b),
some patients with covariate values > 1 have been recruited and this encourages recruitment of
negative covariate values. At t = 267 days no primary events have occurred. In (c), after t = 268
days the first primary event occurs for a patient with a positive covariate value. This additional
piece of information further increases the benefit of recruiting negative covariate values over positive
ones. Note that the vertical scale changes. This illustrates that the recruitment probability changes
dynamically, and depends on the observed events and covariate values of the existing cohort. We
conclude that in general we gain more information from covariate values that have been under-
sampled or values where few primary events have occurred.
Individuals with covariates values far from zero will have the greatest reduction in expected
entropy. This is because these terms will dominate the data likelihood in a proportional hazards
model. Consequently, the covariate distribution in the ACT can differ considerably from the pop-
ulation distribution. Figure 3 shows the empirical covariate distributions for the original dataset
and both trials. Due to the shape of the expected entropy function (see Figure 2) patients towards
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Figure 2: The expected entropy (9) as a function of x at various times during the ACT.
±1 were more likely to be recruited in the ACT. Consequently, almost no patients with x ≈ 0 were
recruited. The RCT density resembles the density of the full dataset.
4 Numerical simulation studies
Here we consider a scenario where the covariates consist of a two-dimensional biomarker yi =
(yi1, yi2) and patients are given one of three treatments denoted by zi = (zi1, zi2, zi3). A patient
given treatment one would have zi = (1, 0, 0), treatment two would have zi = (0, 1, 0), and so forth.
We are interested in whether there is any interaction between the biomarker and treatments, i.e. is
the biomarker predictive. A proportional hazards model with interaction terms is assumed:
h(t|yi, zi, λ,β) = λeβ1yi1zi1+β2yi1zi2+β3yi1zi3+β4yi2zi1+β5yi2zi2+β6yi2zi3 . (13)
This gives a total of six regression coefficients and the baseline hazard λ to be inferred. In all
simulations we compared an adaptive trial to a randomised one.
To simulate survival data we generate a random vector y = (y1, y2) where yi ∼ uniform(−1,+1)
or yi ∼ N (0, 0.5) for i = 1, 2. A treatment arm z is chosen (either randomly or according to (11)).
A random number w ∼ uniform(0, 1) is generated, and an event time is given by the inverse of
the cumulative distribution t = −e−β·x log(1 − w)/λ where x ∈ R6 contains the same product
terms between y and z as (13). Patients are censored at random with probability pc ∈ [0, 1]. If an
individual is censored then the time-to-censoring is drawn from a uniform density between 0 and t.
The first patient to be generated is recruited onto both the ACT and RCT. The waiting time until
the next patient is drawn from an exponential density with rate parameter ξ. Hyperparameters
were set to (κ0, χ0, α
2
0) = (3, 1, 4).
β1 β2 β3 β4 β5 β6 λ
ACT (Uniform) 0.348 0.374 0.361 0.384 0.418 0.352 0.00080
RCT (Uniform) 0.364 0.347 0.401 0.389 0.396 0.384 0.00084
ACT (Gaussian) 0.499 0.5120 0.487 0.438 0.445 0.430 0.00085
RCT (Gaussian) 0.470 0.494 0.504 0.471 0.518 0.435 0.00084
Table 2: Mean square error between inferred and ‘true’ model parameters over 500 simula-
tions. Comparison between both random and adaptive trials without selective recruitment
and uniform and Gaussian distributed covariates.
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Figure 3: Kernel smoothed empirical covariate densities (Gaussian kernel, bandwidth = 0.2)
for (a) the full GBCS dataset, (b) the ACT, and (c) the RCT. Due to the shape of the
expected entropy function (see Figure 2) patients towards ±1 were more likely to be recruited
in the ACT. Consequently, almost no patients with x ⇡ 0 were recruited. The RCT density
resembles the density of the full dataset.
3.2 Numerical simulation studies
Here we consider a scenario where the covariates consist of a two-dimensional biomarker yi =
(yi1, yi2) and patients are given one of three treatments denoted by zi = (zi1, zi2, zi3). A patient
given treatment one would have zi = (1, 0, 0), treatment two would have zi = (0, 1, 0), and so forth.
We are interested in whether there is any interaction between the biomarker and treatments, i.e. is
the biomarker predictive. A proportional hazards model with interaction terms is assumed:
h(t|yi, zi, , ) =  e 1yi1zi1+ 2yi1zi2+ 3yi1zi3+ 4yi2zi1+ 5yi2zi2+ 6yi2zi3 . (11)
This gives a total of six regression coe cients and the baseline hazard   to be inferred. In all
simulations we compared an adaptive trial to a randomised one.
To simulate survival data we generate a random vector y = (y1, y2) where yi ⇠ uniform( 1,+1)
for i = 1, 2. A treatment arm z is chosen (either randomly or adaptively). A random number w ⇠
uniform(0, 1) is generated, and an event time is given by the inverse of the cumulative distribution
t =  e  ·x log(1  w)/  where x 2 R6 contains the same product terms between y and z as (11).
Patients are censored at random with probability pcens 2 [0, 1]. If an individual is censored then the
time-to-censoring is drawn from a uniform density between 0 and t. The first patient to be generated
is recruited onto both the ACT and RCT. The waiting time until the next patient is drawn from
an exponential density with rate parameter ⇠. Hyperparameters were set to (0, 0,↵
2
0) = (3, 1, 4).
 1  2  3  4  5  6  
ACT 0.376 0.367 0.360 0.385 0.361 0.385 0.00083
RCT 0.386 0.396 0.373 0.371 0.366 0.399 0.00080
Table 2: Mean square error between inferred and ‘true’ model parameters over 1,000 simu-
lations. Comparison between random and adaptive trials without selective recruitment.
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4.1 Adaptive allocation without selective recruitment
In these simulations all patients were recruited. A total of N = 50 patients were recruited onto both
trials. The trial was terminated after t = 100 arbitrary units of time. The rate parameter for waiting
times as ξ = 6, nd pc = 0.5. Model param ters were set to β = (0.8,−0.5, 1.1,−0.7, 0.6, 0.1)
and λ = 0.1. In the ACT th exp cted entropy was used t determine which treatment rm each
individual was allocated to s described in Section 2.4. In the RCT patients were allocated o one
of the thre arms at random.
A tot l of 500 s mulations were run. We computed the mean square ror between the inferred
model parameters and the ‘true’ values used to generate the data. As shown in Table 2 we found
essentially no difference between the randomised and adaptive trials for either uniformly or Gaussian
distributed covariates. We found that the entropy at the end of the ACTs with uniform covariates
was on average slightly lower than the RCTs (2.14 and 2.20 respectively), although the difference
was statistically significant (p-value 0.017 with a one-sided paired t-test). For Gaussian distributed
covariates the difference in entropies was insignificant. We also performed a chi-squared test to
see if the allocation proportions of patients across arms differed from a uniform distribution. Each
simulated trial was tested and we found no p-values less than 0.05 for either uniform or Gaussian
distributed covariates. Since the chi-squared test was repeated for each trial the p-values were
corrected for multiple hypothesis testing by controlling the false discovery rate (using the method
of Benjamini and Hochberg (1995)) with the ‘p.adjust’ R function.
4.2 Adaptive allocation and recruitment
In these simulations the same parameters as above were used but patients were recruited onto the
ACT selectively with a threshold of p0 = 0.66. Over 500 simulations we found that the mean
square error between the inferred and ‘true’ parameters was considerably lower in the ACTs than
the RCTs as shown in Table 3. For uniformly distributed covariates 48.9% of the inferred parameter
values were significant (at 0.05) in the ACT compared to 39.2% in the RCTs. Furthermore, the
mean entropy at the end of the ACTs was 0.93, compared to 2.23 in the RCTs. On average 140.7
(standard deviation 42.9) individuals are rejected.
In the case of Gaussian distributed covariates the difference is more pronounced. 50.4% of
parameters were significant in the ACT compared to 35.0% in the RCT. An average of 240.0
patients were rejected (standard deviation 61.9). Due to the Gaussian distribution there are more
patients in the less informative region around zero. Therefore the number of rejections is higher
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β1 β2 β3 β4 β5 β6 λ
ACT (uniform) 0.324 0.279 0.313 0.342 0.279 0.306 0.00079
RCT (uniform) 0.401 0.335 0.408 0.375 0.367 0.361 0.00081
ACT (Gaussian) 0.266 0.289 0.278 0.217 0.253 0.262 0.00085
RCT (Gaussian) 0.444 0.553 0.509 0.521 0.502 0.478 0.00082
Table 3: Mean square error between inferred and ‘true’ model parameters over 500 simula-
tions. Comparison between random and adaptive trials with selective recruitment.
and the benefit more substantial.
We also explored the effect of the threshold p0 on the trial results. When p0 = 0.33 we found
that the MSE (averaged over the six beta values) was 0.287 in the ACT compared to 0.372 in the
RCT with 44.0% of inferred parameters reaching statistical significance in the ACT compared to
39.6% in the RCT. An average of 22.0 patients were rejected (standard deviation 6.45). When
the threshold was increased to p0 = 0.90 the MSE was 0.358 versus 0.363, and the proportion of
significant parameters was 41.7% versus 39.3%, in the RCT and ACT respectively. On average
237.3 (standard deviation 86.5) patients were rejected. This suggests that setting the threshold too
high can be counterproductive.
5 Discussion
The practicality of our proposed design will depend on various economic and ethical considerations
as well as the characteristics of each particular trial and the study population. For instance, if a
covariate is relatively inexpensive to measure when compared to the costs of recruitment (treat-
ment provision, follow-up, administration) then it may be sensible to selectively recruit informative
patients. A large pool of patients can be inexpensively screened and then resources concentrated on
those which are likely to provide the most information. In this case a selective recruitment design
could result in significant cost reductions since fewer recruits are required overall.
Clinical trials are not primarily intended to be therapeutic, but rather as a means to generate
medical evidence. Recruited patients may be exposed to treatments that are ineffective (e.g. a
placebo) or that are possibly even harmful. Our proposed design offers the possibility to conduct
a trial using fewer patients than a traditional randomised design. This may be ethically attrac-
tive in some cases since ultimately fewer patients are offered treatment options with uncertain
efficaciousness.
In a selective recruitment design the decision to recruit and allocate a patient can also take into
account the probability of a successful response to treatment (although this was outside the scope
of this paper). Patients can be recruited and allocated in a manner that balances the statistical
informativeness of a decision against the potential benefit or harm to that individual. The decision
making process must balance individual and collective benefits. Maximising statistical information
offers a collective benefit to all patients outside the trial (both current and future) who could benefit
from the trial findings. Naturally this must be offset by what is best for the trial participants. What
our proposed design offers the practitioner is a framework to balance individual versus collective
ethical considerations.
Selective recruitment designs suffer from a number of drawbacks, one of which is longer recruit-
ment times. If the patient accrual rate is low it may render the overall recruitment period unfeasible.
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Selective recruitment designs are therefore only appropriate in situations where patients accrue rel-
atively quickly or where longer recruitment periods are an acceptable compromise.
One of the consequences of a proportional hazards model is that the most informative patients
tend to have extreme values of covariates. As a result the distribution of recruited patients may
differ from the population distribution which might make it difficult to generalise results from
the trial to the general population. Thus, some generalisability is sacrificed in return for greater
statistical power. If this was deemed undesirable one could introduce a sufficient level of random
sampling in addition to preferential accrual of informative patients. Each candidate patient has a
minimum probability of recruitment with informative patients having a higher probability. Thus,
selective recruitment need not be an all or nothing process; it can be used to enrich the trial with
informative patients to a desired degree.
Finally, in the case of model misspecification undesirable biases may be introduced into the
dataset because the model choice influences the covariate distribution considerably. An additional
limitation is that it is not yet clear how to estimate the sample size required for a certain level of
statistical power — a calculation that is typically used when planning new trials.
In summary, our novel information-adaptive selective recruitment clinical trial design will re-
ject non-informative patients. Individuals who are more likely to clarify the values of our model
parameters are more likely to be recruited. We have demonstrated with both experimental and
simulated data the feasibility of our approach. Statistically significant inferences can be achieved
using fewer patients with a selective recruitment design than a randomised trial, although we found
that treatment arm allocation using an entropy based measure (without selective recruitment) did
not offer any improvement over a randomised design. Such a design may offer a more economical or
ethically attractive route to discover the relationship between biomarkers, treatments, and survival
outcomes.
It will be interesting to extend this work beyond the proportional hazards assumption to more
complex survival models. Incorporation of response-adaptive protocols offer another promising
extension. Throughout this work we have assumed a uniform population density. In the case of a
non-uniform density it may be desirable to incorporate this into the definition of an ideal candidate
such that an ideal candidate is both informative and likely to be observed. This will require further
investigation. Further extensions of the model could include alternative outcomes such as binary
or continuous measurements.
A Derivation of the Kullback-Leibler divergence
The first two terms of the Kullback-Leibler divergence (8) in Section 2.3 are simply minus the
entropies of the variational distributions. These are 〈log q(λ)〉q(λ) = −(1/2 + log(2piσ21)/2 +µ1) and
〈log q(β)〉q(β) = −
∑d
ν=1 log(2pieσ
2
0ν)/2. The third term from (8) is
−N1t 〈log λ〉q(λ) −Φt · 〈β〉q(β) + 〈λ〉q(λ)
Nt∑
i=1
ti
〈
eβ·xi
〉
q(β)
− 〈log p(λ|κ0, χ0)〉q(λ) −
〈
log p(β|α20)
〉
q(β)
(14)
where N1t is the number of non-censored events up until time t and Φt =
∑
i:∆i=1
xi. It is straight-
forward to show 〈log λ〉q(λ) = µ1, 〈λ〉q(λ) = eµ1+σ
2
1/2 and 〈β〉q(β) = µ0. The following result is
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needed (Coolen et al., 2005, Appendix D):∫
dz
e−
1
2 (z−µ)·A−1(z−µ)+b·z
(2pi)d/2|A|1/2 = e
µ·b+ 12b·Ab (15)
from which it follows
〈
eβ·xi
〉
q(β)
= eµ0·xi+
1
2xi·Σ0xi . Note that (15) also defines the moment generat-
ing function for a multivariate normal distribution with mean µ and covariance matrix A. The terms
relating to the priors are
〈
log p(β|α20)
〉
q(β)
= −∑ν(σ20ν + [µ0]2ν)/2α20 and 〈log p(λ|κ0, χ0)〉q(λ) =
(κ0 − 1) 〈log λ〉q(λ) − χ−10 〈λ〉q(λ) where [µ0]ν denotes the νth component of µ0.
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